Table 2. Center-specific associations of SUA levels (mg/dl) with SLC2A9 SNP.
| All | Arizona | Dakotas | Oklahoma | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
SNP |
Risk allele/frequency |
Effect size (%)a |
P-value |
Risk allele/frequency |
Effect size (%) |
P-value |
Risk allele/frequency |
Effect size (%) |
P-value |
Risk allele/frequency |
Effect size (%) |
P-value |
| rs16890979 | A/0.47 | 4.6 | 1.3E−31 | A/0.55 | 3.8 | 3.8E−11 | A/0.42 | 3.2 | 1.1E−8 | A/0.43 | 5.1 | 7.8E−13 |
| Post. Probb | 0 | 0.12 | 0 | 0 | ||||||||
| rs6832439 | A/0.47 | 4.5 | 7.7E−31 | A/0.55 | 3.8 | 2.8E−11 | A/0.41 | 3.3 | 1.5E−8 | A/0.47 | 4.8 | 7.2E−12 |
| Post. Probb | 0 | 0.09 | 0 | 0 | ||||||||
| rs6449213 | G/0.28 | 4.5 | 1.5E−29 | G/0.37 | 3.0 | 1.6E−11 | G/0.20 | 3.3 | 2.8E−9 | G/0.27 | 6.4 | 1.2E−14 |
| Post. Probb | 1.0 | 0.10 | 1.0 | 1.0 | ||||||||
| rs13131257 | A/0.48 | 4.5 | 1.8E−29 | A/0.56 | 4.2 | 5.8E−12 | A/0.42 | 3.3 | 5.0E−8 | A/0.46 | 4.1 | 2.6E−10 |
| Post. Probb | 0 | 0.43 | 0 | 0 | ||||||||
| rs737267 | A/0.49 | 4.4 | 2.9E−29 | A/0.56 | 4.1 | 9.1E−12 | A/0.45 | 3.1 | 4.5E−8 | A/0.48 | 4.4 | 1.1E−10 |
| Post. Probb | 0 | 0.21 | 0 | 0 | ||||||||
| rs10805346 | A/0.29 | 4.1 | 5.4E−28 | A/0.21 | 4.1 | 2.4E−11 | A/0.39 | 3.3 | 1.4E−8 | A/0.34 | 2.7 | 1.6E−8 |
| Post. Probb | 1.0 | 1.0 | 1.0 | 0 | ||||||||
| rs12498956 | C/0.47 | 3.4 | 5.1E−23 | C/0.43 | 3.3 | 5.9E−10 | C/0.49 | 2.1 | 1.0E−5 | C/0.49 | 4.1 | 1.1E−9 |
| Post. Probb | 0 | 0.05 | 0 | 0 | ||||||||
a
Effect size – proportion of residual phenotypic variance that is explained by the SNP.
b
Post. Prob – posterior probability of a functional effect. Posterior probability of >0.95 is considered as statistically significant evidence of functional effect.
Final model included covariates age, sex, age × sex, body mass index (BMI), eGFR, type 2 diabetes status, self-reported alcohol intake and medications.